Boundless Bio (BOLD) Fundamental Analysis: Revenue, Earnings & Valuation

3.23 / 10

Netural

Fundamental analysis rates BOLD at 3.2/10, indicating weakness. Positive drivers include PB‑ROE, Cash‑MV, inventory turnover and high YoY revenue growth, while Asset‑MV and revenue‑to‑market value lag. Gross margin is low and cost‑of‑sales high, suggesting limited profitability.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score1/3

Weight12.25%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.16%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.25%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.15%

1M Return-0.63%

PB-ROE

Value-0.90

Score2/3

Weight15.37%

1M Return6.97%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.94%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.09%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.40%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight29.14%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight14.43%

1M Return5.94%

Is BOLD fundamentally strong?

BOLD scores 3.23/10 on fundamentals and holds a Fair valuation at present. Backed by its -46.69% ROE, 0.00% net margin, -0.42 P/E ratio, 0.25 P/B ratio, and 32.47% earnings growth, these metrics solidify its Netural investment rating.